A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis

Autor: Yiu, ZZN, Mason, KJ, Barker, JNWN, Hampton, PJ, McElhone, K, Smith, CH, Warren, RB, Griffiths, CEM, Lunt, M, Burden, AD, Study Group, BADBIR

Publikováno v: The British Journal of Dermatology
Yiu, Z Z N, Mason, K J, Barker, J N W N, Hampton, P J, McElhone, K, Smith, C H, Warren, R B, Griffiths, C E M, Lunt, M & Burden, A D 2019, ' A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis ', British Journal of Dermatology . https://doi.org/10.1111/bjd.17849

Summary Background Patients recruited in randomized controlled trials (RCTs) for biologic therapies in psoriasis are not fully representative of the real‐world psoriasis population. Objectives Firstly, to investigate whether patient characteristics

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::038c4f12ba259f0b976cbdefb61e60c1
http://europepmc.org/articles/PMC6916305

Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study

Autor: Pan, S., Tsakok, T., Dand, N., Lonsdale, D.O., Loeff, F.C., Bloem, K., de Vries, A., Baudry, D., Duckworth, M., Mahil, S., Pushpa-Rajah, A., Russell, A., Alsharqi, A., Becher, G., Murphy, R., Wahie, S., Wright, A., Griffiths, C.E.M., Reynolds, N.J., Barker, J., Warren, R.B., David Burden, A., Rispens, T., Standing, J.F., Smith, C.H., Benham, M., Evans, I., Hussain, S., Kirby, B., Lawson, L., Mason, K., McElhone, K., Ormerod, A., Owen, C., Barnes, M.R., Di Meglio, P., Emsley, R., Evans, A., Payne, K.

Publikováno v: CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 13(2), 400-409. Wiley-Blackwell
Clinical and Translational Science, Vol 13, Iss 2, Pp 400-409 (2020)
Clinical and Translational Science
Pan, S, Tsakok, T, Dand, N, Lonsdale, D O, Loeff, F C, Bloem, K, de Vries, A, Baudry, D, Duckworth, M, Mahil, S, Pushpa-Rajah, A, Russell, A, Alsharqi, A, Becher, G, Murphy, R, Wahie, S, Wright, A, Griffiths, C E M, Reynolds, N J, Barker, J, Warren, R B, David Burden, A, Rispens, T & Standing, J F & Smith, C H 2020, ' Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis : A Prospective Pharmacokinetic-Pharmacodynamic Study ', Clinical and Translational Science, vol. 13, no. 2, pp. 400-409 . https://doi.org/10.1111/cts.12725, https://doi.org/10.1111/cts.12725
Pan, S, Tsakok, T, Dand, N, Lonsdale, D O, Loeff, F C, Bloem, K, de Vries, A, Baudry, D, Duckworth, M, Mahil, S, Pushpa-Rajah, A, Russell, A, Alsharqi, A, Becher, G, Murphy, R, Wahie, S, Wright, A, Griffiths, C E M, Reynolds, N J, Barker, J, Warren, R B, David Burden, A, Rispens, T, Standing, J F, Smith, C H, Benham, M, Evans, I, Hussain, S, Kirby, B, Lawson, L, Mason, K, McElhone, K, Ormerod, A, Owen, C, Barnes, M R, Di Meglio, P, Emsley, R, Evans, A & Payne, K 2020, ' Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study ', Clinical and Translational Science, vol. 13, no. 2, pp. 400-409 . https://doi.org/10.1111/cts.12725

Variation in response to biologic therapy for inflammatory diseases, such as psoriasis, is partly driven by variation in drug exposure. Real-world psoriasis data were used to develop a pharmacokinetic/pharmacodynamic (PK/PD) model for the first-line

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bcea23ca63518fef3372a4c62f0df85
https://pure.amc.nl/en/publications/using-realworld-data-to-guide-ustekinumab-dosing-strategies-for-psoriasis(356fdda6-87b8-4fbc-8cc1-218c18c81fd8).html

Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Autor: Rungapiromnan, W, Mason, KJ, Lunt, M, McElhone, K, Rutter, MK, Warren, RB, Griffiths, CEM, Ashcroft, DM, Grp, BADBIRS

Background\ud The cardiovascular safety profile of biologic therapies used for psoriasis is unclear.\ud \ud Objectives\ud To compare the risk of major cardiovascular events (CVE s; acute coronary syndrome, unstable angina, myocardial infarction and s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::749b488351b8d274b4c281508ed51993
https://eprints.keele.ac.uk/8508/1/jdv.16018.pdf

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Autor: Yiu, ZZN, Ashcroft, DM, Evans, I, McElhone, K, Lunt, M, Smith, CH, Walton, S, Murphy, R, Reynolds, NJ, Ormerod, AD, Griffiths, CEM, Warren, RB, Study Group, BADBIR

BACKGROUND: Patients with psoriasis and clinicians are concerned that infliximab may be associated with a risk of serious infections. OBJECTIVES: To compare the risk of serious infections associated with infliximab in patients with chronic plaque pso

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::8cf6a3a4c015a21fa372ed481c660cf1

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.